Ann: Q3 FY23 Quarterly Investor Presentation, page-2

Key Highlights

• Personal Testing revenues up 48% on the prior corresponding period (pcp) driven by both international (up 42%) and domestic testing (up 53%)
• Operational countries up from 4 to 13 YTD, with the addition of Poland, Hungary, Romania, Croatia, Türkiye and Czech Republic during the quarter
• Positive uptake of Microba’s new MetaXplore healthcare test, with >300 Australian healthcare professional accounts registered in the first 7 weeks following launch
• Inflammatory Bowel Disease Program – MAP 315 approved to commence Phase I
• Immuno-Oncology Program – Positive first animal model data
• Autoimmune Disease Program – Positive first in vitro results
• Q3 FY23 unaudited revenue totalled $1.01m, up 61% on the pcp with Personal Testing up 48% to $0.61m and Research Services up 86% to $0.40m
• YTD FY23 unaudited revenue of $3.16m, up 12% on the pcp with Personal Testing up 16% to $1.79m and Research Services up 6% to $1.37m
• Q3 FY23 cash receipts totalling $1.24m, representing 22% growth on the pcp
• YTD FY23 cash receipts totalling $4.65m, representing 45% growth on the pcp
• $35.40 million in cash or equivalents as at 31 March 2023

Not bad at all.